← Evidence map

ArticleBiomedical reports2026

Tafolecimab mitigates ox-LDL-induced macrophage foam cell formation and inflammation by modulating SR-A/ABCG1 expression and inhibiting the NF-κB/MAPK pathways.

Xinyi Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Tafolecimab mitigates ox-LDL-induced macrophage foam cell formation and inflammation by modulating SR-A/ABCG1 expression and inhibiting the NF-κB/MAPK pathways. | OpenQuestion